机译:Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Velindre Cancer Centre,Velindre Canc Ctr;
Ctr Trials Res,Cardiff Univ;
All Wales Lab Genet ServCardiff & Vale Univ Hlth BoardBetsi Cadwaladr Univ Hlth BoardBlackpool Teaching Hosp NHS Fdn TrustUniv Hosp Morecambe Bay NHS Fdn TrustUniv LeedsIpswich Hosp NHS TrustVelindre Canc CtrOncol R&D,AstraZeneca;
RESISTANT PROSTATE-CANCER; DOUBLE-BLIND; MULTICENTER; ALPELISIB; PREDNISOLONE; MONOTHERAPY; MUTATIONS;